GlassScriptPhysician profile
Lawrence L Chao
NPI 1700896370
$17,197.56
in general payments reported to CMS, 2019-2025
38 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,682 · 2020: $2,244 · 2021: $2,860 · 2022: $2,258 · 2023: $2,623 · 2024: $2,320 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,138 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,138.11 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,596.51 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,072.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $1,775.52 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,412.30 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $1,370.78 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $1,183.22 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,035.14 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $672.99 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $648.61 | 2021-2025 | |
| Lilly USA, LLC | $636.98 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $522.73 | 2019-2025 | Otezla, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $400.04 | 2019-2024 | Eliquis |
| Abbvie INC. | $390.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $350.77 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $277.87 | 2019-2025 | Zoryve |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.